Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...
5don MSN
Cancer is swiftly becoming a major health issue in India, affecting both urban and rural populations due to various factors. Innovative treatments like immunotherapy, targeted therapy, and gene ...
Three new cancer treatments are to be made available on the NHS in Scotland, as six drugs are given the green light for use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback